Easter may be over, but momentum across life sciences is building. Anglonordic Life Science Conference is less than two weeks away, alongside a steady stream of clinical progress, partnerships, and industry milestones, it’s all go! Our latest Optimum TV episode features Stephen Hansen of BioCentury and offers fresh insights into market trends and the Q2 […]
There’s now a good deal of observational data suggesting that GLP-1s do indeed cut the chance of developing obesity-related cancer – possibly by up to 40 per cent. But we all know that correlation and causation are not the same thing. So a group of Manchester University academics is planning to run a large study aimed at producing a definitive answer. They […]
Laigo Bio completed final close of oversubscribed €17 million seed financing Laigo Bio, a biotech company pioneering novel and highly differentiated therapies using its proprietary SureTACs™ precision membrane protein degradation platform, announced the successful completion of the second close of its seed financing round, securing an additional €5.5m, bringing the total raised to €17m. This […]
For Britons of a certain age, the phrase “Don’t mention the war” needs no introduction. It’s the most famous line from the most famous episode of the 1970s comedy series Fawlty Towers, in which an inept British hotelier manages to repeatedly insult his German guests. The line is now sometimes used here as a coded instruction to avoid any difficult or awkward subject. But it can be used literally too. So, is there a degree […]
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease R1 Therapeutics, Inc, a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with kidney disease, announced its launch with an oversubscribed $77.5 million Series A financing, along with the […]
